P3, N=422, Not yet recruiting, Nantes University Hospital

P2, N=24, Recruiting, Thirty Respiratory Limited | Not yet recruiting --> Recruiting

P4, N=843, Completed, VA Office of Research and Development | Active, not recruiting --> Completed

P2, N=20, Recruiting, Italian Sarcoma Group

To explore the effect of the combination of Bupleuri Radix and Paeoniae Radix Alba on the high mobility group box-1 protein(HMGB1)/receptor for advanced glycation end-products(RAGE)/nuclear factor-κB(NF-κB) signaling pathway in rats with cholestatic hepatitis induced by rifampicin(RFP). Forty-two male SD rats were randomly divided into the normal group, the Bupleuri Radix-Paeoniae Radix Alba group(C-B group), the RFP group, the ursodeoxycholic acid(UDCA)+RFP group(UDCA+RFP group), the Bupleuri Radix+RFP group(C+RFP group), the Paeoniae Radix Alba+RFP group(B+RFP group), and the Bupleuri Radix-Paeoniae Radix Alba+RFP group(C-B+RFP group)...Compared with the C-B+RFP group, the ALT activity and the protein expression levels of HMGB1, RAGE, IL-6, and GRP78 were significantly higher in the C+RFP and the B+RFP groups. In conclusion, the combination of Bupleuri Radix and Paeoniae Radix Alba alleviates endoplasmic reticulum stress through the HMGB1/RAGE/NF-κB signaling pathway and reduces inflammatory responses, thereby exerting hepatoprotective effects.

P2, N=29, Active, not recruiting, Mayo Clinic | Trial primary completion date: May 2027 --> Sep 2026

P3, N=732, Active, not recruiting, University of Cape Town | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Jun 2024 --> Dec 2025

P1, N=200, Recruiting, University of Virginia | Not yet recruiting --> Recruiting

P2, N=29, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=46 --> 29

P=N/A, N=428, Recruiting, First Affiliated Hospital of Fujian Medical University

The cytotoxic mechanism of action was characterized by a decreased cell viability, morphological alterations, elevation of intracellular ROS, decreased mitochondrial potential, mitochondrial and nuclear dysmorphologies, activation of caspases 9 and 3/7 and apoptosis occurrence, and decreased long-term colony formation. These findings show that SIL could represent a potential alternative therapy for HPV-negative OPSCC by triggering mitochondrial apoptosis and exerting a decline in the colonogenicity of Detroit 562 cancer cells.

Our study is the first collection of a large number of lung cancer patients with brain metastasis taking silibinin, which is very well tolerated and allows patients to maintain a good QoL.